In the Claims

1. (Original) A benzomorpholine derivative or pharmaceutically acceptable salt thereof represented by formula I,



(I)

wherein

A is C_{2-4} alkylene, C_{2-4} alkenylene, or C_{2-4} alkynylene,

R^1 is:

(1) unsubstituted aryl or heteroaryl, or aryl or heteroaryl substituted with one or a plurality of substituents independently selected from the following group,

a) C_{1-5} alkyl, b) C_{1-5} alkoxy c) C_{3-8} cycloalkyl, d) C_{1-5} haloalkyl, e) phenyl, f) phenoxy, g) hydroxyl, h) C_{1-5} hydroxyalkyl, i) C_{1-5} haloalkyloxy, j) mercapto, k) C_{1-5} alkylthio, l) C_{1-5} haloalkylthio, m) halogen, n) cyano, o) nitro, p) amino, q) C_{1-5} alkylamino, r) C_{2-10} dialkylamino, s) acyl, t) carboxyl, u) C_{2-6} alkyloxycarbonyl, v) mesyl, w) trifluoromethanesulfonyl, and x) tosyl; or

(2) unsubstituted C_{1-5} alkyl, C_{3-8} cycloalkyl, C_{2-10} alkenyl, C_{4-10} cycloalkenyl, or C_{2-10} alkynyl, or C_{1-5} alkyl, C_{3-8} cycloalkyl, C_{2-10} alkenyl, C_{4-10} cycloalkenyl, or C_{2-10} alkynyl substituted with one or a plurality of substituents independently selected from the following group,

a) phenyl, b) hydroxyl, c) C_{1-5} alkyl, d) C_{3-8} cycloalkyl, e) C_{1-5} haloalkyl, and f) halogen;

R^2 is unsubstituted aryl or heteroaryl, or aryl or heteroaryl substituted with one or a plurality of substituents independently selected from the following group,

a) C_{1-5} alkyl, b) C_{1-5} alkoxy, c) C_{3-8} cycloalkyl, d) C_{1-5} haloalkyl, e) phenyl, f) phenoxy, g) hydroxyl, h) C_{1-5} hydroxyalkyl, i) C_{1-5} haloalkyloxy, j) mercapto, k) C_{1-5} alkylthio, l) C_{1-5} haloalkylthio, m) halogen, n) cyano, o) nitro, p) amino, q) C_{1-5} alkylamino, r) C_{2-10} dialkylamino, s) acyl, t) carboxyl, u) C_{2-6} alkyloxycarbonyl, v) mesyl, w) trifluoromethanesulfonyl, and x) tosyl;

R^3 is hydrogen, halogen, C_{1-5} alkyl, or C_{1-5} alkoxy; R^4 is $-X-(CH_2)n-COOR^5$, and X is –O–, –S–, or $-CH_2-$; R^5 is hydrogen or C_{1-5} alkyl; and n is an integer that is 1, 2, or 3.

2. (Currently Amended) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 1 represented by ~~general~~ formula (II),



(II)

wherein A, R^1, R^2, R^3, and R^4 are as defined in claim 1.

3. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein A is ethylene.

4. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 is unsubstituted aryl or heteroaryl, or aryl or heteroaryl substituted with one or a plurality of substituents which are as defined in claim 1.

5. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 4, wherein R^1 is unsubstituted phenyl, furyl, thienyl, or pyridyl, or phenyl, furyl, thienyl, or pyridyl substituted with one or a plurality of substituents which are as defined in claim 1.

6. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 5, wherein R^1 is unsubstituted phenyl, furyl, thienyl, or pyridyl, or phenyl, furyl, thienyl, or pyridyl substituted with one or a plurality of substituents independently selected from the following group,

a) C_{1-5} alkyl, b) C_{1-5} alkoxy, c) C_{1-5} haloalkyl, d) hydroxyl, e) C_{1-5} haloalkyloxy, f) C_{1-5} alkylthio, g) C_{1-5} haloalkylthio, h) halogen, i) cyano, j) C_{2-10} dialkylamino, k) acetyl, l) C_{2-6} alkyloxycarbonyl, m) mesyl, n) trifluoromethanesulfonyl, and o) tosyl.

7. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 6, wherein R^1 is unsubstituted phenyl, furyl, thienyl, or pyridyl or phenyl, furyl, thienyl, or pyridyl substituted with one or a plurality of substituents independently selected from the following group,

a) C_{1-5} alkyl, b) C_{1-5} alkoxy, c) C_{1-5} haloalkyl, d) hydroxyl, h) halogen, and i) cyano.

8. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein R^2 is unsubstituted phenyl or pyridyl, or phenyl or pyridyl substituted with one or a plurality of substituents which are as defined in claim 1.

9. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof

according to claim 8, wherein R^2 is unsubstituted phenyl or pyridyl, or phenyl or pyridyl substituted with one or a plurality of substituents independently selected from the following group,

a) C_{1-5} alkyl, b) C_{1-5} alkoxy, c) C_{1-5} haloalkyl, d) hydroxyl, e) C_{1-5} haloalkyloxy, f) C_{1-5} alkylthio, g) C_{1-5} haloalkylthio, h) halogen, i) cyano, j) amino, k) C_{2-10} dialkylamino, l) acyl, m) C_{2-6} alkyloxycarbonyl, n) mesyl, o) trifluoromethanesulfonyl, and p) tosyl.

10. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 9, wherein R^2 is unsubstituted phenyl or pyridyl, or phenyl or pyridyl substituted with one or a plurality of substituents independently selected from the following group,

a) C_{1-5} alkyl, b) C_{1-5} alkoxy, c) C_{1-5} haloalkyl, d) C_{1-5} haloalkyloxy, e) C_{1-5} alkylthio, f) halogen, and g) C_{2-10} dialkylamino.

11. (Original) The benzomorpholine derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein X is –O–.

12. – 16. (Cancelled)

17. (Previously Presented) A pharmaceutical composition comprising:

a pharmaceutically acceptable carrier; and

a benzomorpholine derivative or pharmaceutically acceptable salt thereof represented by formula I,



(I)

wherein

A is C_{2-4} alkylene, C_{2-4} alkenylene, or C_{2-4} alkynylene,

R^1 is:

(1) unsubstituted aryl or heteroaryl, or aryl or heteroaryl substituted with one or a plurality of substituents independently selected from the following group,

a) C_{1-5} alkyl, b) C_{1-5} alkoxy c) C_{3-8} cycloalkyl, d) C_{1-5} haloalkyl, e) phenyl, f) phenoxy, g) hydroxyl, h) C_{1-5} hydroxyalkyl, i) C_{1-5} haloalkyloxy, j) mercapto, k) C_{1-5} alkylthio, l) C_{1-5} haloalkylthio, m) halogen, n) cyano, o) nitro, p) amino, q) C_{1-5} alkylamino, r) C_{2-10} dialkylamino, s) acyl, t) carboxyl, u) C_{2-6} alkyloxycarbonyl, v) mesyl, w) trifluoromethanesulfonyl, and x) tosyl; or

(2) unsubstituted C_{1-5} alkyl, C_{3-8} cycloalkyl, C_{2-10} alkenyl, C_{4-10} cycloalkenyl, or C_{2-10} alkynyl, or C_{1-5}

alkyl, C_{3-8} cycloalkyl, C_{2-10} alkenyl, C_{4-10} cycloalkenyl, or C_{2-10} alkynyl substituted with one or a plurality of substituents independently selected from the following group,

a) phenyl, b) hydroxyl, c) C_{1-5} alkyl, d) C_{3-8} cycloalkyl, e) C_{1-5} haloalkyl, and f) halogen;

R^2 is unsubstituted aryl or heteroaryl, or aryl or heteroaryl substituted with one or a plurality of substituents independently selected from the following group,

a) C_{1-5} alkyl, b) C_{1-5} alkoxy, c) C_{3-8} cycloalkyl, d) C_{1-5} haloalkyl, e) phenyl, f) phenoxy, g) hydroxyl, h) C_{1-5} hydroxyalkyl, i) C_{1-5} haloalkyloxy, j) mercapto, k) C_{1-5} alkylthio, l) C_{1-5} haloalkylthio, m) halogen, n) cyano, o) nitro, p) amino, q) C_{1-5} alkylamino, r) C_{2-10} dialkylamino, s) acyl, t) carboxyl, u) C_{2-6} alkyloxycarbonyl, v) mesyl, w) trifluoromethanesulfonyl, and x) tosyl;

R^3 is hydrogen, halogen, C_{1-5} alkyl, or C_{1-5} alkoxy; R^4 is $-X-(CH_2)n-COOR^5$, and X is –O–, –S–, or $-CH_2-$; R^5 is hydrogen or C_{1-5} alkyl; and n is an integer that is 1, 2, or 3.

18. (New) A method of treating or preventing thrombosis or diseases accompanying thrombus comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 17 to a subject.

19. (New) The method according to claim 18, wherein the thrombosis is in coronary arteries, cerebral arteries, peripheral arteries, or peripheral veins.

20. (New) The method according to claim 18, wherein the disease is myocardial infarction, unstable angina, cerebral infarction, transient ischemic attack, or peripheral arterial occlusive disease.

21. (New) A method of inhibiting or preventing platelet aggregation comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 17 to a subject.